Abstract:Background Rheumatic mitral stenosis is a significant cause of valvular heart disease. Pulmonary arterial systolic pressure (PASP) reflects the hemodynamic consequences of mitral stenosis and is used to determine treatment strategies. However, PASP progression and expected outcomes based on PASP changes in patients with moderately severe mitral stenosis remain unclear. Methods and Results A total of 436 patients with moderately severe rheumatic mitral stenosis (valve area 1.0–1.5 cm 2 ) were enrolled. Composite outcomes included all‐cause mortality and hospitalization for heart failure. Data‐driven phenotyping identified 2 distinct trajectory groups based on PASP progression: rapid (8.7%) and slow (91.3%). Patients in the rapid progression group were older and had more diabetes and atrial fibrillation than those in the slow progression group (all P <0.05). The initial mean diastolic pressure gradient and PASP were higher in the rapid progression group than in the slow progression group (6.2±2.4 mm Hg versus 5.1±2.0 mm Hg [ P =0.001] and 42.3±13.3 mm Hg versus 33.0±9.2 mm Hg [ P <0.001], respectively). The rapid progression group had a poorer event‐free survival rate than the slow progression group (log‐rank P <0.001). Rapid PASP progression was a significant risk factor for composite outcomes even after adjusting for comorbidities (hazard ratio, 3.08 [95% CI, 1.68–5.64]; P 40 mm Hg was independently associated with allocation to the rapid progression group (odds ratio, 4.95 [95% CI, 2.08–11.99]; P <0.001). Conclusions Rapid PASP progression was associated with a higher risk of the composite outcomes. The main independent predictor for rapid progression group allocation was initial PASP >40 mm Hg. Nonstandard Abbreviations and Acronyms LCTM latent class trajectory modeling MV mitral valve MVA mitral valve area MVR mitral valve replacement PASP pulmonary arterial systolic pressure PBMC percutaneous balloon mitral commissurotomy TTE transthoracic echocardiography Clinical Perspective What Is New? This study leveraged a longitudinal value to evaluate the long‐term trajectories of hemodynamic progression in patients with moderately severe rheumatic mitral stenosis. Two distinct trajectories were identified according to the progression of pulmonary arterial systolic pressure (PASP). The rapid progression of PASP was a significant prognostic factor for poorer clinical outcomes during a 10‐year follow‐up, and initial PASP >40 mm Hg was an independent determining factor for rapid progression group allocation. What Are the Clinical Implications? Careful clinical attention, including more frequent follow‐up, is warranted for patients with rapid PASP progression. These results imply that patients with PASP >40 mm Hg, atrial fibrillation, and diabetes may require closer follow‐up with increased surveillance with echocardiography because of the risk of a rapid increase in PASP. Rheumatic heart disease is a significant global health issue, with 282 000 new cases occurring annually. 1 At least 15.6 million people are estimated to be living with rheumatic heart disease worldwide, and the prevalence of heart failure (HF) attributable to rheumatic heart disease increased by 88% from 1990 to 2015. 1 , 2 The mitral valve (MV) is the valve most frequently affected by rheumatic fever, and mitral stenosis (MS) develops as a result of repeated or persistent valvulitis. 3 , 4 Current guidelines define severe or significant MS as MV area (MVA) <1.5 cm. 5 , 6 However, previous studies investigating MS prognosis have commonly targeted patients with MVA ≤1.0 cm 2 based on prior guidelines. 7 , 9 Th -Abstract Truncated-

Incidence and predictors of adverse outcomes in patients with rheumatic mitral stenosis following percutaneous balloon mitral valvuloplasty: a study from a tertiary center in Thailand

Clinical Effect of Percutaneous Balloon Mitral Valvuloplasty in Treatment of Rheumatic Mitral Stenosis

Clinical application of percutaneous balloon mitral valvuloplasty in patients with rheumatic mitral stenosis and left atrial thrombi

Effects of Percutaneous Balloon Mitral Valvuloplasty on Plasma B-type Natriuretic Peptide in Rheumatic Mitral Stenosis with and Without Atrial Fibrillation.

A study of Clinical Profile and in Hospital Outcomes of patients undergoing Percutaneous Transvenous Mitral Commissurotomy at a Tertiary Care Center of Nepal

Revisiting percutaneous balloon mitral valvotomy technique and safety in various population: an evidence-based case report and literature review

Influence of Right Atrial Pressure on the Prognosis of Patients with Rheumatic Mitral Stenosis Undergoing Percutaneous Mitral Balloon Valvuloplasty

Short Term and Long-Term Results of Percutaneous Balloon Mitral Valvuloplasty in Patients with Mitral Stenosis and Atrial Fibrillation

Abstract 13445: The Prognostic Value of Pulmonary Hypertension and Atrial Fibrillation in Rheumatic Mitral Stenosis

Childbearing Performances and Outcomes of Female Patients with Rheumatic Mitral Valve Diseases after Different Mitral Interventions

Evaluation on Results of Repeat Percutaneous Balloon Mitral Valvuloplasty for Mitral Restenosis Following Prior Balloon Valvuloplasty

Clinical characteristics and long-term outcome of patients with bioprosthetic mitral valve- Experience from a South Asian country

3-Year Outcomes of Mitral Valve-in-Valve Therapy Using Balloon Expandable Transcatheter Valves in the United States

Identification of Distinct Subgroups in Moderately Severe Rheumatic Mitral Stenosis Using Data-Driven Phenotyping of Longitudinal Hemodynamic Progression.

Pulmonary artery pressure response to percutaneous mitral valvuloplasty: Associated factors and clinical implications

Impact of Mitral Stenosis on Early and Late Outcomes of Transcatheter Aortic Valve Replacement for Aortic Stenosis: A Single-Center Analysis

Impact of commissural calcification on clinical outcome of percutaneous balloon mitral valvuloplasty; a retrospective cohort study of 876 patients

One-Year Outcomes of Transseptal Mitral Valve-in-Valve in Intermediate Surgical Risk Patients

Midterm Outcome of Valve Repair for Rheumatic Mitral Stenosis: 6-year Experience in a Single Mid-Volume Cardiac Center

Natural History of Mitral Regurgitation After Transcatheter Aortic Valve Implantation

Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series